Related Experiment Videos
Acute left ventricular failure following melphalan and fludarabine conditioning
D S Ritchie1, J F Seymour, A W Roberts
1Bone Marrow Transplant Service, Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia.
Bone Marrow Transplantation
|August 11, 2001
Summary
Severe heart failure is a rare complication of melphalan and fludarabine chemotherapy. This combination, used before stem cell transplants, caused left ventricular failure in 3 of 21 patients, a previously unreported cardiotoxicity.
Area of Science:
- Hematology
- Oncology
- Cardiology
Background:
- Melphalan and fludarabine are used as single agents with rare cardiotoxicity.
- These agents are now combined for non-myeloablative conditioning chemotherapy before allogeneic stem cell transplantation.
Observation:
- Severe left ventricular failure was observed in 3 out of 21 patients receiving the melphalan and fludarabine combination therapy.
- This cardiotoxicity was not previously reported in the context of this specific chemotherapy regimen.
Findings:
- The combination of melphalan and fludarabine prior to allogeneic stem cell transplantation can lead to severe left ventricular failure.
- This represents a novel finding regarding the cardiotoxic potential of this combined chemotherapy regimen.
Implications:
- Clinicians should be aware of the potential for severe cardiotoxicity when using melphalan and fludarabine in combination.
- This finding necessitates careful patient assessment, monitoring for cardiac function, and consideration of treatment modifications for patients undergoing this pre-transplant conditioning.
- Further research is warranted to understand the mechanisms and management of this specific cardiotoxicity.